A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Conditions
- Non-Small Cell Lung Cancer
Interventions
- DRUG: Durvalumab
- DRUG: Domvanalimab
- OTHER: Placebo
Sponsor
AstraZeneca
Collaborators